Our observations are interesting for 2 principal reasons. First, we show that CNV in DHRD is sensitive to treatment with intravitreal bevacizumab, providing indirect evidence that vascular endothelial growth factor may play a role in this disease. This is significant because patients who develop CNV have a poor prognosis and our observations may help guide other clinicians who are presented with this condition. Second, we show that VA recovered well following resolution of CNV, suggesting that the loss of retinal function may be reversible. This observation needs to be confirmed with a larger number of patients but, if consistent, would argue strongly for an early intervention with anti–vascular endothelial growth factor treatments when CNV complicates DHRD.